Technical Analysis for GTHX - G1 Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical GTHX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.96% | |
| Lower Bollinger Band Walk | Weakness | -1.96% | |
| Inside Day | Range Contraction | -1.86% | |
| BB Squeeze Ended | Range Expansion | -1.86% | |
| Below Lower BB | Weakness | -1.86% | |
| Lower Bollinger Band Touch | Weakness | -1.86% | |
| MACD Bearish Signal Line Cross | Bearish | -1.53% | |
| Bollinger Band Squeeze | Range Contraction | -1.53% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2019
- Sector: Healthcare
- Industry: Biotechnology
G1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.
Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Hormones Astrazeneca Protein Kinase Inhibitors Her2/Neu Treatment Of Breast Cancer Antiestrogens
Biopharmaceutical Cancer Drugs Treatment Of Cancer Breast Cancer Hormones Astrazeneca Protein Kinase Inhibitors Her2/Neu Treatment Of Breast Cancer Antiestrogens
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
See more GTHX news...
| Indicator | Value |
|---|---|
| 52 Week High | 41.8 |
| 52 Week Low | 13.87 |
| Average Volume | 399,763 |
| 200-Day Moving Average | 24.16 |
| 50-Day Moving Average | 22.62 |
| 20-Day Moving Average | 22.41 |
| 10-Day Moving Average | 21.87 |
| Average True Range | 1.36 |
| ADX | 39.04 |
| +DI | 9.92 |
| -DI | 30.72 |
| Chandelier Exit (Long, 3 ATRs ) | 20.69 |
| Chandelier Exit (Short, 3 ATRs ) | 23.24 |
| Upper Bollinger Band | 24.36 |
| Lower Bollinger Band | 20.45 |
| Percent B (%b) | 0.02 |
| BandWidth | 17.44 |
| MACD Line | -0.67 |
| MACD Signal Line | -0.52 |
| MACD Histogram | -0.1496 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.37 | ||||
| Resistance 3 (R3) | 22.41 | 21.84 | 22.07 | ||
| Resistance 2 (R2) | 21.84 | 21.37 | 21.82 | 21.96 | |
| Resistance 1 (R1) | 21.19 | 21.09 | 20.91 | 21.15 | 21.86 |
| Pivot Point | 20.62 | 20.62 | 20.48 | 20.60 | 20.62 |
| Support 1 (S1) | 19.97 | 20.15 | 19.69 | 19.93 | 19.22 |
| Support 2 (S2) | 19.40 | 19.87 | 19.38 | 19.12 | |
| Support 3 (S3) | 18.75 | 19.40 | 19.02 | ||
| Support 4 (S4) | 18.71 |
